The TRIB3 expression that was increased by ATRA/As2O3 treatment further impeded PPARγ activity by forming the heterotrimer of TRIB3, PML-RARα and PPARγ, contributing to dyslipidemia in APL patients undergoing anti-APL therapy. Here, PPARG is linked to metabolic syndrome.